This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017 Sep;12(9):1338-1340.

doi: 10.1016/j.jtho.2017.07.001.

Optimal Treatment of Stage IIIA-N2 Non-Small Cell Lung Cancer: A Neverending Story?

Paul E Van Schil¹

Affiliations

PMID: 28838709
DOI: 10.1016/j.jtho.2017.07.001

Free article

Editorial

Optimal Treatment of Stage IIIA-N2 Non-Small Cell Lung Cancer: A Neverending Story?

Paul E Van Schil. J Thorac Oncol. 2017 Sep.

Free article

. 2017 Sep;12(9):1338-1340.

doi: 10.1016/j.jtho.2017.07.001.

Author

Paul E Van Schil¹

Affiliation

¹ Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Antwerp, Belgium. Electronic address: paul.van.schil@uza.be.

PMID: 28838709
DOI: 10.1016/j.jtho.2017.07.001

No abstract available

PubMed Disclaimer

Comment on

Resectable Clinical N2 Non-Small Cell Lung Cancer; What Is the Optimal Treatment Strategy? An Update by the British Thoracic Society Lung Cancer Specialist Advisory Group.
Evison M, Clive A, Castle L, Powell H, Thomas R, Buttery R, Masani V, Harden S, West D, Woolhouse I. Evison M, et al. J Thorac Oncol. 2017 Sep;12(9):1434-1441. doi: 10.1016/j.jtho.2017.05.023. Epub 2017 Jun 15. J Thorac Oncol. 2017. PMID: 28624466

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information